HLA Class II-DRB,-DQA and-DQB genotypes in peripheral blood shows shifts during the course of sepsis by Bara, Linda et al.
INTRODUCTION
Sepsis is the leading cause of death in the intensive care unit
and ranks in the top ten causes of death in general world-
wide (Leentjens et al., 2013). The mortality rate of severe
sepsis remains high (approximately 30%) despite improved
clinical management algorithms (Levy et al., 2010).
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Undeniably, sepsis is still a profoundly damaging and life-threatening condition for many individu-
als. With multiple changes in sepsis patients it is difficult to precisely classify an individual’s re-
sponse in sepsis as proinflammatory or immunosuppressed. The aim of this study was to
investigate genetically determined predisposition to developed sepsis by analysis of distribution of
human leukocyte antigen (HLA) class II genes. Samples from patients with sepsis were collected
at Pauls Stradiòð Clinical University Hospital, Latvia, in an intensive care unit between October
2016 and May 2017. The study group included 62 patients with sepsis, who were genotyped for
HLA-DR; DQ using real time polymerase chain reaction – sequence specific primer (RT
PCR-SSP). As a control group, data of 100 individuals were taken from the genetic bank of RSU
Joint Laboratory of Clinical Immunology and Immunogenetics. The summarised results showed
that the frequency of alleles DRB1*04:01 (OR = 5.54; 95% CI = 1.88–16.29); DRB1*07:01 (OR =
19.03; 95% CI = 2/37–152.82); DQA1*05:01 (OR = 14.17; 95% CI = 5.67–35.4); and DQB1*02:01
(OR = 50.00; 95% CI = 2.90–861.81) were significantly increased in patients with sepsis com-
pared to the control group patients. The frequency of DRB1*16:01 (OR = 0.17, 95% CI =
0.04–0.59); DRB1*17:01 (OR = 0.04; 95% CI = 0.00–0.69); DQA1*01:01 (OR = 0.04; 95% CI =
0.00–0.31); DQA1*01:02 (OR = 0.03; 95% CI = 0.00–0.23); DQB1*02:02 (OR = 0.12; 95% CI =
0.03–0.42) alleles was lower in sepsis patients than in control subjects. The most frequent
HLA-DRB1/DQA1/DQB1 haplotypes that was significantly increased in patients with sepsis were:
DRB1*01:01/DQA1*05:01/DQB1*03:01 (OR = 12.6; 95% CI = 1.51–105.0; p < 0.003). Sepsis pa-
tients with pneumonia and alleles and DRB1 04:01; 07:01, DQB1 02:01 had the highest mortality
rate. Undoubtedly, our preliminary data showed that development of sepsis can be associated
with alleles and haplotypes of HLA class II genes. For more precise conclusion the research
should be continued to include a larger patient group.
Key words: genetic, human leukocyte antigen, sepsis, associated genes, major histocompatibility
complex.
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Despite improvement in patient care, septic syndromes re-
main a public health challenge (Annane et al., 2005; Cazalis
et al., 2014).
Sepsis development involves an active inflammatory reac-
tion with massive release of proinflammatory cytokines.
The release of these cytokines is associated with high mor-
tality and development of organ dysfunction (Hotchkiss and
Karl, 2003; Monneret et al., 2008; Hutchins et al., 2014).
Despite the extended laboratory and clinical study of sepsis,
its diagnosis remains a clinical challenge. The initiation of
sepsis activates many different biochemical and immuno-
logical pathways, which is expressed with alterations of
many molecules of human tissues. The detection and the
measurement of the concentration of such molecules,
known as biomarkers, may be a diagnostic tool of great sig-
nificance when the clinicians approach patients with sus-
pected sepsis. Additionally, they may be used to predict
outcome and therefore they may have a role in the monitor-
ing of the response to therapy. There is a search for an ideal
biomarker, which will enable sepsis patients to be identified
in a timely manner and to prevent serious conditions and
death (Payen et al., 2013).
A large number of genes that are known or predicted to
have immunologic function reside alongside the human leu-
kocyte antigen (HLA) genes, including HLA-II class
(DRB1; DQA1; DQB1); HLA-III class (heat shock protein
(HSP) molecules; complement factor B; complement com-
ponents 2, 4A, and 4B; TNF-a and TNF-b (lymphotoxin)
(Mato et al., 2009).
The classical HLA loci are class I (HLA-A, -B, -C, -E, -F,
and -G) and class II (HLA-DR, -DQ, -DM, and -DP) mole-
cules identified for their role in presentation of antigen to
CD8+ and CD4+ T cells, respectively. They are encoded by
a 4-Mb region of human chromosome 6p21, which is recog-
nised as the most variable region in the human genome and
which has been designated the major histocompatibility
complex (MHC) because of the important role played by
class I and class II molecules in recognition of self versus
nonself (Horton et al., 2008).
The location of genes encoding classical HLA molecules in
close proximity to so many other immune-related genes
poses huge problems in trying to tease out the critical ge-
netic/functional variants that might play a role in complex
diseases such as sepsis (Burton et al., 2005; Blackwell et
al., 2009).
The choice for study of the regions DRB1, DQA1, and
DQB1 was due to their crucial role in encoding the HLA
class II molecules. HLA-DR consists of one - and one
-chain, respectively encoded by one -gene and four func-
tional -genes, called HLA-DRB1, -DRB3, -DRB4, and
-DRB5. HLA-DRB1 is constitutively always present with
more than 100 different alleles. The individual HLA-DRB
haplotypes correspond to the presence or absence of a spe-
cific combination between a HLA-DRB1 gene and other
DRB genes on each chromosome 6 (Choi et al., 2011).
HLA-DQ regions, especially the exons 2 and 3 that encode
the 1 and 1 chains of the HLA-DQ subunits A1 and B1,
are the regions that form the antigen cleft, where most of
the genetic polymorphisms are concentrated (Shimokawa et
al., 2016).
Technological, pharmacological, and surgical methods have
improved the outcomes of many diseases. However, despite
the efforts in developing diagnostic tools, such as scoring
systems for predicting the outcome in case of critical ill-
nesses, intensive care doctors are still unable to predict the
outcome in all patients, especially for sepsis patients (Wat-
son et al., 2003).
Extensive studies investigating the host responses during
sepsis have revealed that the late phase of sepsis is domi-
nated by a status of immune suppression with respect to
missing or widespread depressed innate, as well as adaptive,
immune defense mechanisms (Angus, 2010; Otto et al.,
2011).
It is necessary to find additional approaches in prognostics
and diagnostics to distinguish between infectious and non-
infectious aetiology.
Moreover, the modern level of development of genetics and
molecular biology has allowed an emphasis of the important
role of genetics in the development of sepsis.
HLA genes have been known for a long time, but interest in
this complex has constantly increased. Many infectious dis-
eases are associated with genetic variation in the HLA class
I and class II gene regions of the major histocompatibility
complex (MHC) on chromosome 6p21.3 (Michalek et al.,
2007; Eglite et al., 2010). HLA class I molecules present
peptide antigens on the surface of almost all cells, whereas
HLA class II molecules present antigens on the surface of
antigen-presenting cells, such as dendritic cells, mono-
nuclear phagocytes, and B cells (Hanna and Etzioni, 2014).
With the discovery of new technologies in molecular genet-
ics, new infomation on genes and allelic specificity is pre-
sented every year (Anonymous, 2018a). Further still, the
studies of contributions of HLA genes in a human body
have almost exclusively focused on antigenic diversity and
specificity. Certain genotypes regulate intercellular homeo-
stasis, also associated with increased production of
immune-stimulatory cytokines on exposure to pathogens.
Sepsis is the result of the interaction between the microor-
ganism and their products and the host factors released on
response (cytokines and other mediators). This host re-
sponse is an innate mechanism developed to protect the or-
ganism from harm, but in sepsis the response is in excess,
with negative effects, leading to organ dysfunction and fre-
quently to death (Jabandziev et al., 2014; Cajander et al.,
2016). Several candidate genes have been identified as im-
portant in the inflammatory response and investigated in
case-controlled studies. These are the HLA DRB1*
DQA1*DQB1* genes, positioned next to each other within
the cluster of human leukocyteantigen class II genes.
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Some previous studies showed that human leucocyte anti-
gen class II (HLA II) alleles may have protective or risk im-
portance in sepsis patients. Our objective was to identify
HLA II class alleles of risk and protection in sepsis patients
compared with control group patients.
These HLA association studies were conducted to identify
disease-specific susceptibility (risk), and to identify protec-
tive markers that could be used in immunogenetic profiling,
risk assessment and therapeutic decisions.
We summarise the evidence for a genetic susceptibility to
develop the sepsis and unfavourable outcome of sepsis. We
consider that the candidate genes are likely to be involved
in the development of sepsis and based on genetic variabil-
ity.
MATERIALS AND METHODS
Patient selection. This was a single-centre study at Pauls
Stradiòð Clinical University Hospital, Latvia. The study
group included patients (n = 62) who had sepsis and were
enrolled during an eight-month period.
Sepsis criteria taken into consideration for including pa-
tients in the study were consecutive hospitalised patients
who had two or more of the following signs during their
first 24 hours in the units were diagnosed as systemic in-
flammatory response syndrome (SIRS): temperature of
> 38 °C or < 36 °C, pulse rate of > 90 beats/min, respiratory
rate of > 20 breaths/min or hyperventilation with partial
pressure of arterial carbon dioxide of < 32 mmHg, or white
blood cell (WBC) count of > 12 000 µL or < 4000 µL, or
> 10% immature cells. Patients exhibiting two or more
signs of SIRS with proven or suspected infection were diag-
nosed as sepsis and included in the study. Exclusion criteria
were: < 18 years of age, acquired immunodeficiency syn-
drome, neutropenia (polymorphonuclear granulocyte count
< 500 µL), or died within 24 hours after admission to the
hospital, elected not to participate in the study, or declined
treatment during the observation period (Angus, 2013).
Ethical approval for the study was obtained from the Ethics
Committee (Rîga Stradiòð University). Written informed
consent was obtained for each patient from the patient him-
self or from relatives.
DNA isolation. Genomic DNA for each individual meeting
sepsis criteria was extracted from peripheral blood on ad-
mission day 1, by using QiagenQIAamp DNA kit reagents
(Qiagen, Assay Technologies), as per the manufacturer’s
protocol (Anonymous, 2016).
HLA-DR and DQ genotyping low resolution by using
RT-PCR. HLA-DR-DQ allele genotyping for simultaneous
detection of DRB1* 01:01 to 18:01 specificity,
DQA1*01:01, 01:02, 01:03, 02:01, 03:01, 04:01, 05:01,
06:01, and for DQB1*02:01-02:02, *03:01-03:05, *04:01-
04:02, *05:01-05:04, and *06:01-06:08 was performed by
RT-PCR qualitative multiplex analysis, using amplification
with sequence-specific primer RT-PCR-SSP HLA-DRB1;
DQA1;DQB1 kits (DNA-Technology, Russia) (Anony-
mous, 2018b).
The reaction PCR mix (35 µl) included 5 µl DNA, and 10 µl
PCR buffer. The PCR-Mix contained an internal control
(DNA-IC). The IC is intended for PCR quality and suffi-
ciency of DNA assurance. Registration and interpretation of
the PCR results held in automatic mode was determined on
a DTLite thermal Cycler (DNA-Technology, Russia). The
HLA-DQA1; DRB1; and DQB1 allele specificities for each
sample were determined by the software version 7.3.5.84
and taking to account the total result from all tubes for each
sample.
The control group included 100 randomly selected healthy
unrelated Caucasians from the same area in Eastern Europe
from the Rîga Stradiòð University, Joint Laboratory of
Clinical Immunology and Immunogenetics. Inclusion crite-
ria were: > 18 years of age, both sexes, no history of a septi-
cemia and other chronic diseases.
Statistical analysis. Allelic frequencies of HLA alleles and
haplotypes were compared between the patients and con-
trols using the chi-square test and fisher’s exact test. The
odds ratio (OR) and confidence interval 95% (CI 95%) were
calculated. The statistical analysis was conducted using
SPSS (Statistical Package for the Social Sciences) (22.0
version) software. A p value < 0.05 was accepted as statisti-
cally significant.
RESULTS
We performed the study with 62 patients with sepsis, men
56.5% (n = 35) and women 43.5% (n = 27), the average age
was 63.4 years (standard deviation 15.9). All patients were
enrolled in the Pauls Stradiòð Clinical University Hospital
of Latvia, in an intensive care unit between October 2016
and May 2017. The most common final clinical diagnosis
was pneumonia 66% (n = 41), followed by complex soft tis-
sue infections 13% (n = 8), surgical pathology 14.5% (n =
9) and urinary tract infection 6.5% (n = 4), The immunoge-
netic part of the study was done at Rîga Stradiòð University
(RSU) Joint Laboratory of Clinical Immunology and Immu-
nogenetics (JLCII). Sixty-two sepsis patients and control
group of 100 healthy individuals were genotyped for HLA-
DRB1; DQB1 and DQA1 using RT-PCR with sequence-
specific primers.
The summarised results showed that frequencies of alleles
DRB1*04:01 (OR = 5.54; 95% CI = 1.88–16.29; p = 0.001);
DRB1*07:01 (OR = 19.03; 95% CI = 2.37–152.82; p =
0.001); DQA1*05:01 (OR = 14.17; 95% CI = 5.67–35.4;
p < 0.001); DQB1*02:01 (OR = 50.00; 95% CI =
2.90–861.81; p < 0.001) were significantly increased in pa-
tients with sepsis compared to the control group patients.
The frequencies of DRB1*16:01 (OR = 0.17; 95% CI =
0.04–0.59; p = 0.002); DRB1*17:01 (OR = 0.04; 95% CI =
0.00–0.69; p = 0.001); DQA1*01:01 (OR = 0.04; 95% CI =
12 Proc. Latvian Acad. Sci., Section B, Vol. 73 (2019), No. 1.
0.00–0.31; p < 0.001); DQA1*01:02 (OR = 0.03; 95% CI =
0.00–0.23; p < 0.001); DQB1*02:02 (OR = 0.12; 95% CI =
0.03–0.42; p < 0.001) alleles were lower in sepsis patients
than in control subjects. Other alleles that were not statisti-
cally significant were not depicted here (Table 1).
The alleles that were significantly increased in patients with
sepsis compared to the control group patients were analysed
in respect to final clinical diagnosis of the sepsis patients
with DRB1*04:01 allele, pneumonia occurred in n = 12
(29.3%) patients and half of these patients died (n = 6,
14.7%); but surgical patology occurred in n = 2 (22.2%) pa-
tients and both of them died (n = 2, 22.2%). For patients
with DRB1*07:01 allele pneumonia was present in n = 4
(9.8%), complex soft tissue infection in n = 1 (12.5%), uri-
nary tract infection in n = 3 (75.0%), surgical patology in
n = 2 (22.0%). One patient with the DRB1* 07:01 allele and
surgical patology died (n = 1, 11.0%). For patients with
DQB1*02:01 allele, pneumonia was present in n = 7
(17.1%) and 3 patients died (n = 3, 8%), complex soft tissue
infection in n = 4 (50.0%), and urinary tract infection in
n = 1 (25.0%). For DQB1*03:02, pneumonia occurred in
n = 7 (17.1%) patients, complex soft tissue infection in
n = 1 (12.5%) and surgical patology in n = 2 (22.2%) (Ta-
ble 2)
The most frequent HLA-DRB1/DQA1/DQB1 haplotype that
was significantly increased in patients with sepsis was
DRB1*01:01/DQA1*05:01/DQB1*03:01 (OR = 12.6; 95%
CI = 1.51–105.0; p 0.003). Of the seven sepsis patients
with this haplotype the most common final clinical diagno-
sis was pneumonia (n = 5, 12.2%), complex soft tissue in-
fection (n = 1, 12.5%) and surgical patology (n = 1, 11.1%).
Slightly increased values in sepsis patients were also ob-
served for haplotypes
DRB1*01:01/DQA1*03:01/DQB1*03:01 (OR = 8.33; 95%
CI = 0.39–176.52; p = 0.071);
DRB1*01:01/DQA1*03:01/DQB1*06:02-8 (OR = 8.33;
95% CI = 0.39–176.52; p = 0.071);
DRB1*04:01/DQA1*05:01/DQB1*03:01 (OR = 8.33; 95%
CI = 0.39–176.52; p = 0.071) and
DRB1*07:01/DQA1*02:01/DQB1*03:03 (OR = 8.33; 95%
CI = 0.39–176.52; p = 0.071), but they were not statistically
significant. None of these haplotypes was observed in the
control group, except for one patient with haplotype
DRB1*01:01/DQA1*05:01/DQB1*03:01 (Table 3).
DISCUSSION
Despite improvement in patient care, septic syndromes re-
main a public health challenge (Annane et al., 2005; Cazalis
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OR (95% CI) p
DRB1*
DRB1*04:01 14 patients (22.6) 5 control subjects (5.0) 5.54 (1.88–16.29) 0.001
DRB1*07:01 10 patients (16.2) 1 (1.0) 19.03 (2.37–152.82) 0.001
DRB1*16:01 3(4.8) 23 (23.0) 0.17 (0.04–0.59) 0.002
DRB1*17:01 0 16 (16.0) 0.04 (0–0.69) 0.001
DQA1*
DQA1*01:01 1(1.6) 28 (28.0) 0.04 (0–0.31) < 0.001
DQA1*01:02 1(1.6) 34 (34.0) 0.03 (0–0.23) < 0.001
DQA1*05:01 32 (51.6) 7 (7.0) 14.17 (5.67–35.4) < 0.001
DQB1*
DQB1*02:01 12 (19.4) 0 50.00 (2.90–861.81) < 0.001
DQB1*02:02 3(4.8) 29 (29.0) 0.12 (0.03–0.42) < 0.001
DQB1*03:02 10 (16.1) 7 (7.0) 2.55 (0.92–7.11) 0.065
n, the number of patients in the group (percent %); OR, odds ratio; CI, confidence interval
T a b l e 2
FREQUENCY OF CLINICAL DIAGNOSES IN CONJUNCTION WITH SPECFIC ALLELES IN SEPSIS PATIENTS
Alleles Pneumonia Complex soft tissue
infection
Urinary tract infection Surgical pathology Total
DRB1*04:01 n = 12 (29.3%) n = 0 (0%) n = 0 (0%) n = 2 (22.2%) n = 14 (22.6%)
DRB1*07:01 n = 4 (9.8%) n = 1 (12.5%) n = 3 (75.0%) n = 2 (22.2%) n = 10 (16.1%)
DQA1*05:01 n = 18 (43.9%) n = 6 (75.0%) n = 2 (50.0%) n = 6 (66.7%) n = 32 (51.6%)
DQB1*02:01 n = 7 (17.1%) n = 4 (50.0%) n = 1 (25.0%) n = 0 (0%) n = 12 (19.4%)
DQB1*03:02 n = 7 (17.1%) n = 1 (12.5%) n = 0 (0%) n = 2 (22.2%) n = 10 (16.1%)
n, the number of patients in the group (percent %)
et al., 2014). Sepsis development involves an active inflam-
matory reaction with massive release of proinflammatory
cytokines. The release of these cytokines is associated with
high mortality and development of organ dysfunction
(Hotchkiss and Karl, 2003; Monneret et al., 2008; Hutchins
et al., 2014).
Research shows that genetic variation in human populations
contributes to susceptibility to infectious disease (Burgner
et al., 2006) and possibly also promoting development of
sepsis.
HLA association studies have been conducted to identify
disease-specific susceptibility (risk), and to find protective
markers that can be used in immunogenetic profiling, risk
assessment and therapeutic decisions. HLA class II mole-
cules are highly polymorphic and play a pivotal role in su-
perantigen presentation to T cells.
It is likely that the severity of sepsis might be influenced by
the presence or absence of one HLA allele or more alleles
forming haplotypes. The present study was conducted to in-
vestigate the association between HLA-DRB1/DQA1/DQB1
alleles and haplotypes with susceptibility or protection to
sepsis.
Our study focused attention on HLA-DRB1, HLA-DQA1
and HLA-DQB1 genes, which belong to a group of MHC
genes called MHC class II genes. MHC class II genes pro-
vide instructions for making proteins that are present on the
surface of certain immune system cells. These proteins at-
tach to protein fragments (peptides) outside the cell. MHC
class II proteins display these peptides to the immune sys-
tem. If the immune system recognises the peptides as for-
eign (such as viral or bacterial peptides), it triggers a re-
sponse to attack the invading viruses or bacteria. Each
MHC class II gene has many possible variations, allowing
the immune system to react to a wide range of foreign in-
vaders.
Among the numerous markers that have been tested for
their capacity to predict mortality in septic patients, the de-
creased expression on circulating monocytes of the major
histocompatibility complex (MHC) class II molecule human
leukocyte antigen-DR (HLA-DR) has proven to be a reli-
able predictor of adverse events (death, secondary noso-
comial infections) in critically ill patients when measured
48 h after inaugural stress/injury (Pachot et al., 2005;
Monneret et al., 2008; Cazalis et al., 2013).
In a 2013 retrospective study of the outcome in 999 patients
with sepsis, the overall mortality was 31%, and the highest
incidence of death (67.3%) was in the late phase, when mul-
tiple organ dysfunction developed (Cajander et al., 2013).
Nevertheless, studies on drugs aimed to prevent this cyto-
kine storm in sepsis patients have been inconclusive (Fisher
et al., 1996; Monneret and Venet, 2015).
In one study, for example, downregulation of monocyte hu-
man leukocyte antigen-DR surface expression (mHLA-DR)
measured by flow cytometry was postulated as a general
biomarker of sepsis-induced immunosuppression and acted
as an independent predictor of nosocomial infections (Lan-
delle et al., 2010).
However, the use of mHLA-DR as a marker of immunosup-
pression has not yet been sufficiently evaluated in large
multicenter studies of patients with sepsis, and this is most
likely due to pre-analytical requirements and limitations in
specimen handling (Cajander et al., 2013).
Our research results also showed that four of the HLA-
DRB1, three of the HLA-DQA1 and two of the HLA-DQB1
alelles were significantly increased in patients with sepsis.
Also, the most common diagnosis in patients with these al-
leles was pneumonia. There was a higher mortality rate in
sepsis patients with pneumonia and certain alleles (DRB1
04:01; 07:01, DQB1 02:01). Therefore, it is important to
identify sepsis in the first hours and to begin rapid antibac-
terial therapy to prevent mortality.
Research has shown that a large number of genes that are
known or predicted to have immunologic function reside
alongside the HLA genes, including HLA class II
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OR (95% CI) p
01:01*/05:01*/03:01* 7(11.3) 1 (1.0) 12.6 (1.51–105.0) 0.003
01:01*/03:01*/03:01* 2 (3.3) 0 (0) 8.33 (0.39–176.52) 0.071
01:01*/03:01*/06:02-8* 2 (3.3) 0 (0) 8.33 (0.39–176.52) 0.071
04:01*/05:01*/03:01* 2 (3.3) 0 (0) 8.33 (0.39–176.52) 0.071
07:01*/02:01*/03:03* 2 (3.3) 0 (0) 8.33 (0.39–176.52) 0.071
12:01*/05:01*/06:02-8* 1 (1.6) 0 (0) - -
13:01*/05:01*/05:01* 1 (1.6) 0 (0) - -
15:01*/02:01*/02:01* 1 (1.6) 0 (0) - -
16:01*/05:01*/06:02-8* 1 (1.6) 0 (0) - -
15:01*/05:01*/03:02* 1 (1.6) 0 (0) - -
n, the number of patients in the group (percent %); OR, odds ratio; CI, confidence interval
(DRB1/DQA1/DQB1) (Kumpf, 2008). Genes involved in
the immune response are the most numerous and the most
diverse in the human genome (Kuniholm et al., 2016).
In our study the polymorphism of the human leucocyte anti-
gen HLA class II-related haplotypes (HLA-DRB1-DQA1-
DQB1) were investigated in sepsis patients and compared
with a control group. In our opinion, it is very important
that only one haplotype HLA-
DRB1*01:01/DQA1*05:01/DQB1*03:01 was significantly
increased in patients with sepsis compared with control
group patients. No other haplotypes were observed in sepsis
patients.
Frequencies of several specific HLA II class alleles signifi-
cantly differed between sepsis and control patients and the
most clinical diagnosis was pneumonia with higher mortal-
ity, followed by complex soft tissue infections. Possibly, the
development of sepsis may be associated with alleles of
HLA class II genes.
For more precise conclusions the research should be contin-
ued with a larger patient group.
Limitation of the study. The findings of this study have to
be taken wih caution since the sample size was relatively
small to draw definitive conclusions. These results need to
be confirmed prospectively in a large population.
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HLA II KLASES -DRB, -DQA UN -DQB GÇNU GENOTIPISKÂS IZMAIÒAS PERIFÇRAJÂS ASINÎS PACIENTIEM AR SEPSI
Sepse joprojâm ir dzîvîbai bîstams stâvoklis daudziem cilvçkiem. Mûsu pçtîjuma mçríis bija noskaidrot ìençtisko predispozîciju sepses
attîstîbai, analizçjot cilvçka leikocîtu antigçnu (HLA) II klases gçnu izplatîbu. Pçtîjumâ tika iekïauti pacienti ar sepsi, kas stacionçti Paula
Stradiòa klîniskajâ universitâtes slimnîcâ laika periodâ no 2016. gada oktobra lîdz 2017. gada maijam. Pçtîjumâ tika iekïauti 62 sepses
pacienti, kuriem tika noteikti HLA II klases -DR un -DQ gçnu varianti izmantojot reâlâ laika polimerâzes íçdes reakciju (RT PCR).
Kontroles grupâ bija 100 veseli indivîdi. Apkopotie rezultâti uzrâdîja, ka alçles DRB1*04:01 (OR = 5.54; 95% CI = 1.88–16.29);
DRB1*07:01 (OR = 19.03; 95% CI = 2/37–152.82); DQA1*05:01 (OR = 14.17; 95% CI = 5.67–35.4); DQB1*02:01 (OR = 50.00; 95%
CI = 2.90–861.81) bija ievçrojami palielinâtas pacientiem ar sepsi salîdzinot ar kontroles grupas indivîdiem. Turpretî sekojoðo alçïu —
DRB1*16:01 (OR = 0.17, 95% CI = 0.04–0.59); DRB1*17:01 (OR = 0.04; 95% CI = 0.00–0.69); DQA1*01:01 (OR = 0.04; 95% CI =
0.00–0.31); DQA1*01:02 (OR = 0.03; 95% CI = 0.00–0.23); DQB1*02:02 (OR = 0.12; 95% CI = 0.03–0.42) — bieþums bija ievçrojami
zemâks tieði sepses pacientiem nekâ kontroles grupai. Sepses pacientiem ievçrojami palielinâts bija haplotips
DRB1*01:01/DQA1*05:01/DQB1*03:01 (OR = 12.6; 95% CI = 1.51–105.0; p < 0.003), salîdzinot ar kontroles grupu. Pacientiem ar
pneimoniju un konkrçtâm alçlçm — DRB1*04:01; 07:01, DQB1*02:01 — novçroja augstâko mirstîbu. Neapðaubâmi, mûsu sâkotnçjie dati
liecina, ka sepses attîstîba var bût saistîta ar HLA II klases gçnu alçlçm. Lai iegûtu precîzâkus secinâjumus, pçtniecîbu ir nepiecieðams
turpinât un sepses pacientu grupa ir jâpalielina.
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